Reference : Current therapies for shingles
Scientific journals : Article
Human health sciences : Dermatology
Current therapies for shingles
Nikkels, Arjen mailto [Université de Liège - ULiège > > Dermatologie >]
Pierard, Gérald mailto [Université de Liège - ULiège > > Dermatopathologie >]
Expert Opinion on Investigational Drugs
Ashley Publications Ltd
Yes (verified by ORBi)
United Kingdom
[en] varicella zoster virus ; antiviral drug ; acyclovir ; herpes zoster
[en] Current management of shingles relies on antiviral therapy. The efficacy of acyclovir in varicella-zoster virus replication is now well established, with a beneficial impact on zoster-associated pain, but its moderate bioavailability renders five oral daily doses mandatory. Recent anti-VZV drug research has been oriented towards agents with increased oral bioavailability. Famciclovir and valaciclovir were originally developed as oral prodrugs for^penciclovir and acyclovir, respectively, but, together with the new antivirals, sorivudine and brovavir, they appear to be effective as oral therapy for shingles. Ongoing clinical trials will determine their relative merits in the management of shingles. The experimental agents H2G, HPMPC, mappicine ketone and A-73209 have potential in the treatment of VZV and are undergoing further investigation and development.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Current therapies for shingles.pdfPublisher postprint1.03 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.